Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
暂无分享,去创建一个
F. Facchiano | L. Mercurio | C. Albanesi | S. Madonna | G. Girolomoni | C. Scarponi | S. Pallotta | M. Morelli